Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

746.74 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EST, Jan 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 15,220
Open 746.74
Bid (Size) 748.00 (2)
Ask (Size) 748.50 (1)
Prev. Close 746.74
Today's Range 746.74 - 746.74
52wk Range 612.70 - 972.53
Shares Outstanding N/A
Dividend Yield 0.70%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
My 10 Top Stocks to Buy to Start the New Year Off Right
Via The Motley Fool
Eli Lilly Adjusts Outlook, CEO David Ricks Explains Revenue Shortfall
Eli Lilly forecasts $45 billion revenue for 2024, 32% higher than last year. Medicare changes and stocking issues impact the revised guidance. 
Via Benzinga

Performance

YTD
-4.03%
-4.03%
1 Month
-4.14%
-4.14%
3 Month
-18.52%
-18.52%
6 Month
-17.54%
-17.54%
1 Year
+17.68%
+17.68%

More News

Read More
Eli Lilly: What's Left To Like? A Lot, Says One Analyst.
Via Investor's Business Daily
Eli Lilly Gets Wall Street Backing After Tuesday’s Turmoil, Stock Rises Premarket As Retail Stays Bullish
Via Stocktwits
Topics Earnings
Exposures Financial
Has Eli Lilly Stock Peaked?
Via The Motley Fool
Best Healthcare Stock to Buy: Eli Lilly vs. Novo Nordisk
Via The Motley Fool
Eli Lilly's Options: A Look at What the Big Money is Thinking
Via Benzinga
Microsoft, Applied Digital, Rigetti Computing, Eli Lilly, Tesla: Why These 5 Stocks Are On Investors' Radars Today
Via Benzinga
US Stocks Edge Higher As Traders Eye Inflation Data And Earnings Season Kickoff
Via Talk Markets
Topics Economy Stocks / Equities
Exposures Interest Rates
Stocks Fail To Rise Despite Benign Producer Inflation, 30-Year Treasury Yields Hit 5%, Ely Lilly Tumbles: What's Driving Markets Tuesday?
Via Benzinga
Topics Economy
Exposures Interest Rates
Eli Lilly Stock Faces Worst Day In Nearly 4 Years On Q4 Weight-Loss Drug Sales Miss, But Retail Bullish On 2025 Projections
Via Stocktwits
Topics Earnings
Exposures Financial
Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Dropped on Tuesday
Via The Motley Fool
Eli Lilly Tumbles On Lowered Guidance As Weight-Loss Drug Sales Slow
Via Investor's Business Daily
Eli Lilly Cuts Q4 Revenue Guidance, Expects Around $5.5 Billion Sales From Weight Loss/Diabetes Drugs, Stock Tanks
Via Benzinga
Eli Lilly: 4 Reasons Investors Shouldn’t Miss This Opportunity
Via MarketBeat
Got $5,000? These 3 Growth Stocks Are Trading Near Their 52-Week Lows.
Via The Motley Fool
Eli Lilly Scoops Up Scorpion Therapeutics' Early-Stage Cancer Program For $2.5 Billion
Via Benzinga
Soricimed Biopharma Appoints Dr. Neil Fleshner as Executive Board Member
Via Newsfile
Exposures Lead
Obesity Treatments, M&A Activity To Take Center Stage During Upcoming JPM Healthcare Conference
Via Benzinga
Medicare To Cover Eli Lilly's Weight Loss Drug Zepbound For Obstructive Sleep Apnea Treatment
Via Benzinga
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.
Via Investor's Business Daily
Topics Artificial Intelligence Government
Exposures Artificial Intelligence Political
How Richard DiMarchi Revolutionized Diabetes Treatment
Via Investor's Business Daily
3 Stocks to Buy for 2025 That Are Practically Money Machines
Via The Motley Fool
This Promising New Alzheimer's Study Could Unlock a Massive Growth Opportunity for Novo Nordisk and Eli Lilly
Via The Motley Fool
Investors Look Back at 2024
Via The Motley Fool
Topics Stocks
Exposures US Equities
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.